Primary sclerosing cholangitis: Difference between revisions

(Text replacement - " pts" to " patients")
(Text replacement - " ==" to "==")
(5 intermediate revisions by 3 users not shown)
Line 1: Line 1:
== Background ==
==Background==
*Autoimmune Dz typically seen in young men  
*Autoimmune disease typically seen in young men  
*Progressive inflammation and fibrosis of intra/extra hepatic bile ducts  
*Progressive inflammation and fibrosis of intra/extra hepatic bile ducts  
*Most (80%) cases are associated with inflammatory bowel dz, typically ulcerative colitis, 10% of patients with ulcerative colitis have PSC  
*Most (80%) cases are associated with [[inflammatory bowel disease]], typically [[ulcerative colitis]], 10% of patients with ulcerative colitis have PSC  
*Increased risk of colon CA in patients with Ulcerative colitis and PSC (more than UC alone) Increased risk of cholangiocarcinoma  
*Increased risk of colon cancer in patients with Ulcerative colitis and PSC (more than UC alone) Increased risk of cholangiocarcinoma  
*Prevalence is 1 to 6 per 100,000 in the U.S  
*Prevalence is 1 to 6 per 100,000 in the U.S


== Clinical Features ==
==Clinical Features==
*Generally asymptomatic but can present with fatigue, [[abdominal pain]], [[jaundice]], cholangitis, puritis, weight loss, or [[fever]]
*Generally asymptomatic but can present with fatigue, [[abdominal pain]], [[jaundice]], cholangitis, puritis, weight loss, or [[fever]]
*Mean age at presentation: 30-40
*Mean age at presentation: 30-40
Line 12: Line 12:
==Differential Diagnosis==
==Differential Diagnosis==


==Diagnosis==
==Evaluation==
*Alkaline phosphatase is usually elevated with mild elevations in aminotransferases  
*Alkaline phosphatase is usually elevated with mild elevations in aminotransferases  
*Bilirubin is typically normal, except when common hepatic duct or common bile duct is involved in late stages of disease
*Bilirubin is typically normal, except when common hepatic duct or common bile duct is involved in late stages of disease
Line 20: Line 20:
*Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease
*Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease


== Treatment ==
==Treatment==
*High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day
*High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day
**May improve liver chemistries but does not slow disease progression and may actually hasten development of portal HTN
**May improve liver chemistries but does not slow disease progression and may actually hasten development of portal hypertension
*Periodic dilation of strictures via ERCP or percutaneous route  
*Periodic dilation of strictures via ERCP or percutaneous route  
*Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation)
*Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation)


== Disposition ==
==Disposition==
*Annual Screening for colon cancer in patients with concomitant [[ulcerative colitis]]
*Annual Screening for colon cancer in patients with concomitant [[ulcerative colitis]]


== See Also ==
==See Also==


==References==
==References==

Revision as of 16:33, 3 August 2016

Background

  • Autoimmune disease typically seen in young men
  • Progressive inflammation and fibrosis of intra/extra hepatic bile ducts
  • Most (80%) cases are associated with inflammatory bowel disease, typically ulcerative colitis, 10% of patients with ulcerative colitis have PSC
  • Increased risk of colon cancer in patients with Ulcerative colitis and PSC (more than UC alone) Increased risk of cholangiocarcinoma
  • Prevalence is 1 to 6 per 100,000 in the U.S

Clinical Features

  • Generally asymptomatic but can present with fatigue, abdominal pain, jaundice, cholangitis, puritis, weight loss, or fever
  • Mean age at presentation: 30-40

Differential Diagnosis

Evaluation

  • Alkaline phosphatase is usually elevated with mild elevations in aminotransferases
  • Bilirubin is typically normal, except when common hepatic duct or common bile duct is involved in late stages of disease
  • Perinuclear antineutrophil cytoplasmic antibody (pANCA) positive in 2/3rds of cases
  • Cholangiography
  • Diagnosis made by ERCP or MRCP, which demonstrates strictures or beading of the intrahepatic or extrahepatic bile ducts
  • Liver biopsy typically shows pericholangitis and periductual fibrosis but is often not diagnostic in early disease

Treatment

  • High dose Ursodeoxycholic acid (UDCA), 25-30mg/kg/day
    • May improve liver chemistries but does not slow disease progression and may actually hasten development of portal hypertension
  • Periodic dilation of strictures via ERCP or percutaneous route
  • Liver Transplant should be offered to those with advanced liver disease or repeated bouts of cholangitis (disease can recur after transplantation)

Disposition

See Also

References

  • Current Clinical Medicine, 2nd edition by Cleveland Clinic